Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
|Articles|July 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
RAS Mutations Enhance Chemotherapy in AML
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.
Advertisement
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.
Articles in this issue
over 18 years ago
National Cancer Survivors Dayover 18 years ago
New Indication for Velcade in Previously Untreated Myelomaover 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedover 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caover 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLover 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caover 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsover 18 years ago
Updated X-ACT Study Results Presentedover 18 years ago
ThromboGenics and BioInvent Announce Alliance with Rocheover 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 TrialAdvertisement
Related to this article
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Preoperative botensilimab plus balstilimab produced a pathologic major response in 36% of patients with pMMR and 100% of those with dMMR resectable colon cancer.
Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.
Advertisement
Advertisement
Trending on CancerNetwork
1
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer
4
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
5